

**Table S1: Lung Adenocarcinoma Patient Clinical Characteristics, Related to Figure 1.**

<b>Characteristic</b>	<b>Patients (N=28)</b>
Sex – no. (%)	
Male	12 (43)
Female	16 (57)
Age – no. (%)	
<70	16 (57)
>70	12 (43)
Smoking Status – no. (%)	
Never Smoker	7 (25)
Smoker	21 (75)
Emphysema – no. (%)	19 (68)
Family History of Cancer – no. (%)	
Lung	5 (18)
Other Cancer	10 (36)
Tumor Size (mm)	
Mean	2.8
Range	1.0 – 7.0
Tumor Size – no. (%)	
≤2 cm	14 (50)
>2 cm	14 (50)
Predominant Morphological Pattern – no. (%)	
Papillary	12 (43)
Acinar	8 (29)
Mucinous	3 (11)
Solid	2 (7)
Lepidic	2 (7)
Fetal	1 (3)
Tumor Stage (NSCLC) – no. (%)	
Stage IA (T1a/bN0M0)	8 (29)
Stage IB (T2aN0M0)	8 (29)
Stage IIA (T1/2N0/1M0)	4 (14)
Stage IIB (T2b/3N1/0M0)	3 (11)
StageIIIA (T1-4N1/2M0)	3 (11)
Tumor Location – no. (%)	
RLL	6 (21)
RUL	6 (21)
RML	2 (7)
LLL	6 (21)
LUL	8 (29)
Mutation Subtypes – no. (%)	
EGFR	8 (29)
KRAS	11 (39)
TP53	8 (29)
with KRAS	4 (14)
ERBB2	2 (7)
CDKN2A	2 (7)
EML4-ALK Fusion	1 (3)
Positive Immunohistochemical Staining – no. (%)	
CK7	3 (11)
TTF1	7 (25)